Detailed price information for Vertex Inc Cl A (VERX-Q) from The Globe and Mail including charting and trades.

The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Read more ...

Savara advances BLA plans with strong molgramostim data, large aPAP market potential, and a reinforced cash position. Find ...

Pove was generally safe and well tolerated with adverse events (AEs) that were mostly mild or moderate in severity. There were no serious adverse events related to povetacicept. The safety data is ...

Abstract: 3-path vertex cover of networks is a typical optimization problem in network science, which has a wide range of applications. Toward a 3-path vertex cover of networks from distributed ...

As the U.S. stock market navigates a mixed landscape with tech shares rebounding and the Dow Jones Industrial Average experiencing declines, investors are closely watching for opportunities amid ...

CRISPR Therapeutics CRSP reported a third-quarter 2025 loss of $1.17 per share, narrower than the Zacks Consensus Estimate of ...

Vertex, Inc. (NASDAQ: VERX) posted double-digit revenue growth in the third quarter of 2025 and announced its first-ever ...

This Employment Ontario program is funded in part by the Government of Canada and the Government of Ontario. Soldiers in Tech proudly welcomes all Canadian Armed Forces veterans, reservists (minimum ...

Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and ...